GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » Additional Paid-In Capital

UroGen Pharma (LTS:0XOD) Additional Paid-In Capital : $793.87 Mil(As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma Additional Paid-In Capital?


UroGen Pharma's quarterly additional paid-in capital increased from Mar. 2024 ($671.44 Mil) to Jun. 2024 ($775.27 Mil) and increased from Jun. 2024 ($775.27 Mil) to Sep. 2024 ($793.87 Mil).

UroGen Pharma's annual additional paid-in capital increased from Dec. 2021 ($475.70 Mil) to Dec. 2022 ($487.79 Mil) and increased from Dec. 2022 ($487.79 Mil) to Dec. 2023 ($614.04 Mil).

UroGen Pharma Additional Paid-In Capital Historical Data

The historical data trend for UroGen Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Additional Paid-In Capital Chart

UroGen Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 407.99 452.53 475.70 487.79 614.04

UroGen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 611.39 614.04 671.44 775.27 793.87

UroGen Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

UroGen Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » Additional Paid-In Capital
Comparable Companies
ITOS ERAS SPRY MLYS ALXO TERN ORIC CHRS MGNX CRBU OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
URGN:USA UR8:Germany
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
Website
https://www.urogen.com
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Headlines

No Headlines